Floatz logo

cs-1008

Liver Neoplasms

Daiichi Sankyomonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Liver Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Tehran University of Medical Sciences
Phase 4BBB
Eloxatin
Shanghai Zhongshan Hospital
Phase 4BB
ALBUMIN AGGREGATED
Sirtex Medical
Phase 4BB
CHLORHEXIDINE
Changhua Christian Hospital
Phase 4BB
FLUOROURACILUM
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4BB

View all 50 →

Same molecule, other indications

cs-1008 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
57 / 100
View asset →
liver cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →